Guidance · ESMA · 9 Sep 2026
ESMA is issuing Guidelines to specify the circumstances in which a supplement is considered to introduce a new type of security not already described in a base prospectus, as required by Article 23(8) of the Prospectus Regulation (PR). These Guidelines aim to align EU-wide supervision, addressing longstanding divergence among National Competent Authorities (NCAs) regarding the use of supplements for new securities, which has led to inconsistent requirements for issuers. The Guidelines clarify that a supplement to a base prospectus shall not be used to introduce a new type of security for which the necessary information has not been included in that base prospectus, unless doing so is necessary to comply with capital requirements under Union or national law. The Guidelines, set out in Annex III of this Final Report, will become effective two months after their publication on ESMA’s website in all official EU languages.
9 September 2026
ESMA32-753890202-3034
ESMA - 201-203 rue de Bercy - CS 80910 - 75589 Paris Cedex 12 - France - Tel. +33 (0) 1 58 36 43 21 - www.esma.europa.eu 2 Final Report Guidelines on supplements which introduce new securities to a base prospectus
Table of Contents
1 Executive Summary ....................................................................................................4
2 Background and consultation ......................................................................................5
3 Feedback statement....................................................................................................6
3.1 Summary of stakeholder feedback .......................................................................7
3.2 ESMA's response to stakeholder feedback ........................................................21
4 Annexes ....................................................................................................................29
4.1 Annex I - Summary of consultation questions.....................................................29
4.2 Annex II - Mandate.............................................................................................30
4.3 Annex III – Guidelines specifying the circumstances in which a supplement is to be
considered to introduce a new type of security that is not already described in a base
prospectus ....................................................................................................................31
1 Executive Summary
Reasons for publication
Article 23(8) of the Prospectus Regulation (PR) requires ESMA to “develop Guidelines to
specify the circumstances in which a supplement is to be considered to introduce a new type of security that is not already described in a base prospectus”. This is related to Article 23(4a) of the PR which states that “a supplement to a base prospectus shall not be used to introduce a new type of security for which the necessary information has not been included in that base prospectus [...]” . ESMA is issuing these Guidelines to align EU-wide supervision on this subject, which has been characterised by longstanding divergence and can lead to different supervisory outcomes, which is recognised in Recital 54 2 of the Listing Act. A significant benefit of the final Guidelines is that their straightforwardness and ease of application are likely to reduce the risk of divergence. This, in turn, should reduce the risk of inconsistent requirements across jurisdictions, such as a scenario where an issuer in one jurisdiction is required to prepare a new base prospectus, while an issuer in another jurisdiction needs only produce a supplement. Overall, ESMA thus considers these Guidelines align with the political goals of the Listing Act. The Guidelines in this Final Report were drafted taking into account the substantial feedback provided to the Consultation Paper published on 18 February 2025 and, notably, the overarching request for clear criteria concerning this subject. The publication of this Final Report was delayed following the conclusion of the consultation on 19 May 2025 due to adjustments made in response to market feedback. These revisions led to a new approach, dependent on the disclosure annexes outlined in Commission Delegated Regulation 2019/980, which were only recently amended. Content The Background and consultation section of this Final Report provides additional commentary about divergence in the supervision of so-called “product supplements” and information about the consultation feedback. The Feedback statement section provides summaries of stakeholder feedback to the consultation and ESMA’s response to all feedback received. The Guidelines themselves are set out in Annex III.
Next Steps
The Guidelines in Annex III will be translated into the official EU languages and published on ESMA’s website. They will become effective two months after their publication on ESMA’s website in all the official languages. 2 Background and consultation
implications, as requiring an issuer to prepare a base prospectus instead of a supplement is a materially different outcome.
3. Such divergent, costly, and inconsistent outcomes are undesirable in the context of the
Listing Act, which seeks convergence, burden reduction, and improved access to capital. Additionally, the complex nature and number of changes in product supplements can pose significant challenges for NCAs during their review process. This can lead to investor protection issues, as NCAs may have less time to thoroughly assess the content of supplements compared to base prospectuses. Therefore, clarifying when a supplement introduces a new type of security is beneficial for both market participants and enhancing investor protection. On 18 February 2025, ESMA published a Consultation Paper proposing two draft Guidelines to address this situation.
4. A total of 39 respondents responded to ESMA’s CP. This high volume of feedback
suggests there was strong interest in the subject. Almost all stakeholders responded to the individual questions in the CP, with 37 or 38 replies per question typically received 4 . A key point is that 24 similar submissions were received from 19 individual firms and 5 associations 5 from one Member State. Otherwise, large associations elsewhere typically submitted “one” response on behalf of all their members. Therefore, readers of this Final Report must take care not to overlook the fact that certain “individual” responses represent the views of many members. The feedback statement tries to identify if respondents were associations or individual firms and tries to point out if geographic origin differs to assist readers in this respect.
5. The publication of this Final Report was delayed following the conclusion of the
consultation due to adjustments made in response to market feedback. These revisions led to a new approach, dependent on the disclosure annexes outlined in Commission Delegated Regulation 2019/980, which were only recently amended. 3 Feedback statement
6. The following sub-sections include summaries of the feedback to the consultation and
ESMA’s response to the feedback received. Since similar points were made in response to Qs 1 to 6, ESMA has addressed all feedback collectively in sub-section 3.2 rather than replying to the feedback to each individual question. Note: References to Annexes and items in this Final Report follow the numbering in the recently amended CDR on scrutiny and disclosure. Consultation Paper 4 One stakeholder provided general remarks only, explaining why 38 was typically the highest count in response to individual questions and not 39. 5 Of which several of the 19 individual firms are also understood to be members.
respondents typically used the numbering from the 'CP Annex (clean)' in ESMA's consultation paper on draft technical advice relating to the PR. Thus, consultation responses that mention Annex 15 from the CP Annex (clean) are cited here as referring to Annex 17 in the amended CDR on scrutiny and disclosure and so on.
3.1 Summary of stakeholder feedback
General feedback provided by respondents about the draft Guidelines 27 general responses were provided of which 24 were from one Member State
7. Twenty-seven respondents comprised of issuer associations and individual firms provided
general comments about the draft Guidelines. Twenty-four were from one Member State. The others included national issuer associations from two other Member States and a panEuropean issuer association.
8. The general and mostly critical comments (featuring in twenty-six of the twenty-seven
responses) reflected the following concerns:
Q1: Do you agree with draft Guideline 1 proposed by ESMA and ESMA’s reasoning? If not, please explain why. 38 responses were provided of which 24 were from one Member State. Agreed with Guideline 1 (four of the thirty-eight respondents)
10. One pan-European investor association supported ESMA's approach to clarify the role of
supplements, agreeing they should only be used to update existing material information and not to introduce new product types. They considered ESMA's approach as important for consistency across Member States, investor protection and issuer confidence. Moreover, while they agreed that product variations could sometimes be addressed using supplements, this should only occur if the underlying structure, risk-return profile, and asset class are already clearly covered in the base prospectus. Otherwise, where a new security introduces materially different risks, payoffs, or underlying exposures, a new prospectus should be required - particularly in the context of distribution to retail investors. The same respondent stated it is essential that NCAs have sufficient time to scrutinise product innovations through a full prospectus review, rather than through a more limited supplement process, to protect investors from being exposed to products that were not properly disclosed or understood at the point of sale.
11. A national investor association and an individual firm 6
fully supported ESMA's approach for similar reasons to those already described. The individual firm added that supplements are not supposed to be used to introduce entirely new securities to a base prospectus.
12. Finally, a national issuer association agreed with the guidelines because they reflect factors
which market participants already consider in their jurisdiction.
Disagreed with Guideline 1
13. The remaining thirty-four responses were against the proposed guidance. While 70% were
from the same Member State and provided almost identical feedback, there was pushback by issuer associations from three other Member States in addition to pushback from issuer associations with a pan-European / "global" focus and a pan-European individual firm. A noteworthy observation is that the negative responses could be described as "issuer focused" as opposed to (retail) investor focused 7 , which reveals a difference in attitude 6 The individual firm in this case should be considered as "other". 7 The classification of respondents can be complex, as there are respondent firms who are likely both “issuers” and “investors”. This observation is thus based on the title of certain respondents, e.g., “issuer [XYZ] association” as well as the emphasis on “burden for issuers” versus “risk to investors” in the feedback provided.
according to whether a stakeholder's focus was ease of issuance versus investor protection.
14. The main arguments against the proposed guidelines were:
volatility and historical performance of the new underlying would follow the same structure, as defined in Annex 17, to those already laid out in the base prospectus.
Q2: Do you agree with draft Guideline 2 proposed by ESMA and ESMA’s reasoning? If not, please explain why. 38 responses were provided of which 24 were from one Member State. Agreed with Guideline 2 (two of the thirty-eight respondents)
15. One national investor association agreed with the guidance in Guideline 2. In their view, it
will require firms to plan ahead and to include all expected product types in their base prospectus, thus minimising uncertainty for all parties by encouraging full and comprehensive disclosure upfront. Moreover, they argued it will help supervisors and investors to clearly understand what kind of products are within the scope of the base prospectus. An individual firm 8 who agreed with the guidance generally subscribed to this reasoning. Mixed views (three of thirty-eight respondents)
16. A pan-European investor association, a pan-European issuer association and a national
issuer association had mixed views. They were not against the guidance and agreed with the overall objective but highlighted the difficulties it will create. For example:
they highlighted the importance of not restricting the introduction of underlyings using supplements, provided that the base prospectus includes essential disclosures such as risk factors and overarching terms and conditions related to that type of underlying.
The guidance is not practical: A common theme across the thirty-four responses
was that the guidance is too restrictive and impractical. It was stated that issuers already try to predict their needs and to front load base prospectuses, but circumstances can change, making the ability to use a supplement important. Respondents argued that issuers will not want to incur the cost, or take the time required, to include mechanics that they do not anticipate being even remotely necessary at the point of programme update. Therefore, in their view, a practical approach is needed to maintain agility in issuances and the use of base prospectuses, which the current guidelines would purportedly undermine. Moreover, a comment interspersed throughout responses to the CP 11 was that Guidelines 1 and 2 together will cause difficulties and so their cumulative effect needs to be considered. to a security which the issuer is already permitted to issue. Similarly, making limited adjustments to existing redemption formulae or formulae for calculating interest or limited changes to risk factors should also be permissible by supplement with respect to securities that are already described in the base prospectus. By contrast and by way of example, if an issuer tried to introduce sustainability-linked securities or crypto-assets as an underlying to a base prospectus not containing any associated general contractual provisions or disclosures, this should not be permitted using a supplement.” 11 This comment was not limited to Guideline 2 per se. It was part of the general narrative in negative feedback towards the Guidelines as a whole and was communicated with varying degrees of nuance.
Oncoming problem in relation to benchmarks and structured products if the general
approach in both guidelines is maintained: A pan-European issuer association and a national issuer association drew attention to a potential major issue that may arise due to ESMA’s proposed guidance and an upcoming change to the EU Benchmarks Regulation applicable as of 1 January 2026. Namely, due to revisions to the EU Benchmarks Regulation, administrators of non-significant benchmarks (such as proprietary indices) will be removed from ESMA’s Article 36 benchmarks register after 30 September 2026. As a result, benchmarks provided by such administrators will not benefit from the reduced disclosure permitted for administrators in ESMA’s Article 36 benchmarks register under item 2.2.2 of Annex . Consequently, this might require index disclosure for every potential index in a base prospectus at the outset and that is not possible from a practical perspective. In their view, an alternative approach is to permit the use of supplements for such index disclosure. And this could possibly be subject to a separate index review process, whereby NCAs review an index description on a standalone basis and approve it for the purposes of a particular programme, also allowing for such information to be otherwise incorporated by reference. Q3: Do you believe draft Guideline 2 will lead to longer and less comprehensible prospectuses? If yes, please explain why and describe how you would solve this issue. 37 responses were provided of which 24 were from one Member State
The guidance will lead to longer base prospectuses: This was the view of two panEuropean issuer associations, four national issuer associations from three different
Member States, and five individual firms from different Member States including one with a pan-European focus. The argument was that if issuers are required to include every potential type of product in their base prospectus, the document will become bloated. It will likely lead to prospectuses describing numerous structural features and securities categories, the majority of which may not even be issued, making it more difficult for investors to filter out the core of securities on offer, thus resulting in less comprehensible prospectuses. 12 Or Annex 15 in the CP Annex (clean) (securities giving rise to payment or delivery obligations linked to an underlying asset).
The guidance will not necessarily lead to longer base prospectuses: This was the
view of one national investor association, one pan-European issuer association, one issuer association with a “global” focus and two national issuer associations. The argument was that the guidance merely reflects an existing practice to front load base prospectuses. Thus, it is unlikely to have a material effect on prospectus length.
37 responses were provided of which 24 were from one Member State.
22. The main views expressed in response to question four are set out under the headings
below.
Green bonds and sustainability-linked notes are new securities
23. A pan-European investor association, a national investor association, and an individual
firm 14, argued that green bonds and sustainability-linked securities are distinct securities.
24. One of the investor associations asked ESMA to explicitly state that green bonds and
sustainability-linked notes should be treated as distinct securities in the guidance unless their specific ESG features are already clearly described in the base prospectus. They argued that although these instruments may share structural similarities with conventional bonds, they introduce material risks and commitments, including sustainability performance targets, reputational exposure, and ESG-related coupon adjustments. And this requires full and transparent disclosure about risks which are not comparable to those relating to financial underlyings, such as currencies or indices. Moreover, they stated that ESG-linked products rely on issuer-level performance, often involving external verification and subjective criteria, thus, to treat them as regular bonds may lead to a shortfall in disclosure and opens the door to greenwashing through ex-post reclassification.
25. Similarly, the other investor association stated that green bonds or sustainability-linked
notes should be treated as separate from regular bonds since these products include distinct commitments and risks such as environmental targets. Investors thus need to clearly understand how these differ from regular bonds. Mixed position
26. One national issuer association argued that it is important to distinguish between
(i) changes that solely affect the use of proceeds and the associated risk factors and (ii) changes that affect the structure of the terms and conditions of the instruments. In their view, the introduction of a green component in a bond typically pertains to the use of proceeds and may necessitate updates to the risk factors, whereas the inclusion of a sustainability-linked feature represents a structural modification of the terms and conditions. As such, they saw a stronger case to use a supplement for "use of proceeds" disclosure in the context of "regular" green bonds than for more structured instruments. CDR on financial information, supplements, advertisements and metadata. The corresponding annex number in the CDR on scrutiny on disclosure, as amended, is Annex 23. 14 The individual firm in this case should be considered as "other".
Green bonds and sustainability-linked notes are not new securities
27. The remaining thirty-three responses generally argued that green bonds and sustainabilitylinked notes are not new securities. While 70% of those responses were from the same
Member State and were similar, national issuer associations from three other Member States, a pan-European issuer association, an issuer association with a "global" focus, and a pan-European individual firm made this argument. It is worth noting that those making the argument could be described as "issuer" rather than (retail) "investor" focused 15, which reveals a difference in attitude according to whether a stakeholder's focus was ease of issuance versus investor protection.
28. The main arguments were as follows and resembled the commentary under question one
about security "type" versus "features":
already includes a non-equity security step-up feature, such as a credit rating related interest rate step-up, then a sustainability-linked note with an interest rate step-up should not be deemed a new security.
Annex 21 (now Annex 23) 16
29. Five issuer associations stated that the oncoming Annex 21 (now Annex 23) cannot be a
basis for determining that a new type of security is included in a base prospectus. In their view, certain annexes are only applicable in connection with certain features of securities and do not affect their legal nature. They stated that the inclusion of a sustainable feature does not change the nature or risk profile of the security, which will still be a bond or structured product.
30. Two of those associations added that, as long as the ESG characteristics do not change
the underlying repayment structure, they should not be considered new types of securities. Only if the ESG components determine the structure and significantly influence the repayment modalities is it then possible to categorise the instrument as a new type of security. Advantage to EuGBs
31. Three issuer associations stated that disadvantaging "other" green bonds relative to those
that fulfil the EuGBs must be avoided. This was in reference to ESMA's consultation paper 17 which spoke about treating information in an EuGB factsheet as Category C information, to facilitate the issuance of EuGBs using incorporation by reference. They noted that "other" green bonds will likely be impacted by the fact that several items in
Annex 21 (now Annex 23) are Category A 18
, thus creating more onerous conditions for them. Moreover, they said this situation presupposes that the planning and documentation of the sustainability aspects of the "other" bonds are at a very advanced stage. However, this may not be the case and the likely consequence of the categories in Annex 21 (now
Annex 23), and the guidance overall, is that "other" green bonds would have to occur
through standalone issues with their own prospectuses.
16 Following the revision of Annex 21 (now Annex 23) since the release of the CP, some comments may be affected. Nevertheless, the feedback statement's narrative reflects the comments as originally submitted. 17 ESMA’s consultation paper on draft technical advice concerning the Prospectus Regulation and on updating the CDR on financial information, supplements, advertisements and metadata. 18 For instance, items 2.1, 2.2, 2.3, 2.4 and 3.1 for green bonds and 4.1.1, 4.1.3 from Annex 21 (now Annex 23) for sustainability-linked bonds. Following the revision of Annex 21 (now Annex 23) since the release of the CP, some comments may be affected. Nevertheless, the feedback statement's narrative reflects the comments as originally submitted.
Q5: Is there another way to approach the subject of these Guidelines in your opinion? If yes, please explain what it is and provide arguments to support your suggested approach. Please also provide examples to illustrate the issue(s) you are solving and how your proposed approach facilitates that end. 37 responses were provided of which 24 were from one Member State.
32. Varied proposals were provided in response to this question. Some were high-level and
general, others were more worked out referring to firm rules to apply to product supplements. General comments - clearer criteria are needed
33. A pan-European investor association and a national investor association suggested that
ESMA could go further by developing a unified framework with clearer definitions and product categories. This would help prevent divergent interpretations by NCAs and promote a more harmonised approach across member states. In their view, a structured classification-based on risk profile, payoff structure, or underlying exposure-could clarify when a supplement is appropriate and when a new prospectus is required.
34. Two national issuer associations stated that an approach could be to define what the
distinguishing criteria for a new type of security are, but it was acknowledged how difficult that is and that, even if such boundaries were accompanied by a non-exhaustive list of examples, it is likely that NCAs would still need to undertake case-by-case assessments.
35. By extension, another individual firm stated that it would be useful to specify the principles
under which a supplement would be sufficient, and under which a new base prospectus would be required. They argued that, in principle, the refinement or the update of terms that are by essence in the base prospectus, and which could not have been specified at the time of the publication of the prospectus, should be allowed via supplement because it does not change the nature of the security. General comments - the approach does not align with the Listing Act
36. Twenty-three respondents from the same Member State set out factors they believed need
to be considered under the Listing Act when finalising the guidance for product supplements. In this respect, they believed:
EU harmonisation for product supplements should be based on the more flexible
approaches currently adopted by some NCAs. This is to be in line with the Listing Act goals of burden reduction and access to capital.
The letter of Article 23(4a) of the PR should not be expanded to prohibit the use of
supplements in situations where, in their view, the PR clearly allows supplements to be used, and which have not raised any concerns from the market.
There were two contrasting positions in response to question six.
The Guidelines will not increase costs
A pan-European investor association, a national investor association and a national issuer
association argued that the Guidelines will not significantly increase costs. The panEuropean investor association stated that plans to issue fundamentally new products are rarely finalised within the 12-month validity of a base prospectus and that, in such cases, a new prospectus is the appropriate means to disclose information about the new product and not a supplement.
Moreover, the pan-European investor association and national investor association added
that the main benefit of the Guidelines lies in increased legal certainty, supervisory convergence, and investor protection, because by clarifying when a supplement is appropriate, they reduce the risk that firms introduce riskier or more complex products without sufficient prior disclosure. This will help to avoid divergent treatment across Member States and to reinforce a level playing field in EU capital markets and is particularly important for retail investor trust. The Guidelines will increase costs
The remaining twenty-six respondents (twenty-three from one Member State, two panEuropean issuer associations and one national issuer association from another Member
State) were very concerned about the implications of the Guidelines in their present form. Each believed the Guidelines will create significant burden for the market and will greatly reduce flexibility in the use of supplements. They argued that the likely consequence of the Guidelines would be the proliferation of new base prospectuses. Twenty-five of these respondents highlighted that the cost of producing a new base prospectus relative to a supplement can range between five to ten times as much and is resource intensive because it takes much longer to produce a base prospectus.
3.2 ESMA's response to stakeholder feedback
Introductory remarks
ESMA welcomes the comprehensive feedback in response to the CP. It is important to
determine the way forward for product supplements, which have generated diverse opinions and convergence issues, as emphasised in Recital 54 of the Listing Act. Several arguments presented in the feedback were previously considered by NCAs, including contrasting views, such as those suggesting that the proposed approach merely mirrors the status quo for product supplements versus those stating that it is overly restrictive and unclear. However, a key takeaway from both positive and negative feedback is that the final Guidelines need to be more clear-cut to ensure regulatory consistency.
Section 3.2 collectively addresses similarities in the responses to questions 1 to 6 of the
CP, by presenting ESMA's rationale for the final Guidelines. The Guidelines incorporate several key themes from the feedback, including (i) the need for a clearer distinction between new "types" of securities and new "features" (ii) the importance of burden reduction and access to capital under the Listing Act and the current emphasis on simplification in the EU (iii) the political significance of ESG-related securities, and (iv) the need to protect investors. Regarding the latter, it is important to ensure that the introduction of new "types" of securities into base prospectuses does not compromise investor protection. Clear boundaries around the use of supplements are therefore necessary.
The final Guidelines provide those boundaries through criteria that can be easily applied.
These criteria should mitigate the complex and nuanced discussions which until now have occurred in relation to product supplements and which are inherent to the question, “what is a new security?”. They consider different types of non-equity securities, such as "plain vanilla" types, structured products with various underlyings, ESG-related securities and ABS securities with concentrated exposure to new credit. A significant benefit of the final Guidelines is that their ease of application is likely to reduce the risk of divergence and inconsistent outcomes across jurisdictions, such as an issuer in one jurisdiction being required to prepare a new base prospectus versus a supplement in another. Overall, ESMA considers these Guidelines will bring significant burden reduction, therefore aligning with the political goals of the Listing Act. Initial proposal and way forward
The CP proposal aimed to clarify the role of a supplement under Article 23 of the
Prospectus Regulation 19 and the type of information that may or not be included in a supplement. To assist this, examples of acceptable and unacceptable disclosures were provided. Further examples were included to the extent that issuers appropriately frontload their base prospectuses. While some respondents, including a national issuer association, believed the proposal mirrored current practices and generally supported it, most feedback suggested the approach was unclear. There were concerns it might lead to restrictive application of the Guidelines and would undermine the burden reduction envisioned under the Listing Act. More direct and clear-cut guidance was deemed necessary to prevent further difficult discussions between issuers and NCAs about the distinction between security "types" and "features", thereby pre-empting impediments to smooth access to capital and continued divergence across NCAs.
The final Guidelines therefore provide clear criteria to identify product supplements, rather
than brief examples and principles relating to product supplements. The revised approach is based on feedback from large issuer associations, who advocated using the disclosure annexes in the CDR on scrutiny and disclosure as the basis to identify a product supplement. ESMA notes this alternative approach was considered in discussions with NCAs prior to the CP and therefore welcomes this suggestion returning in the feedback. Moreover, this approach would not appear to be an issue for those who were more supportive of the CP proposal. Notably, since they emphasised the need for convergence 19 Article 23 on supplements to the prospectus states: “(1) Every significant new factor, material mistake or material inaccuracy relating to the information included in a prospectus which may affect the assessment of the securities and which arises or is noted between the time when the prospectus is approved and the closing of the offer period or the time when trading on a regulated market begins, whichever occurs later, shall be mentioned in a supplement to the prospectus without undue delay. […].”
and investor protection, both of which may be better achieved through this approach, which provides a clearer basis to identify product supplements. Overview of Annex-based approach to be applied going forward
50. The final Guidelines methodically outline how to determine if disclosure in a supplement
introduces a new type of security, based on the annexes in the CDR on scrutiny and disclosure. A first and general Guideline focuses on new disclosure from an annex that was not previously applicable to the base prospectus. Three subsequent Guidelines focus on disclosure for structured instruments, requiring an analysis of targeted information items within the annexes, such as for structured products, ABS securities, and sustainabilitylinked securities. More information about this "refined" approach is provided below. Guideline 1 Guideline 1: If a supplement involves disclosure from the following securities note annexes or building blocks that did not apply to the securities included in the base prospectus, the supplement should be treated as introducing a new “type” of security, and a new base prospectus should be required:
relevant variables and ESMA guidance. A reference to crypto assets as an underlying asset was therefore added to the proposed list as well as material from ESMA Q&A 12.2 20 or 1015 21 . Additionally, for thoroughness, a reference to Item 3.1.7 (a) of Annex 14, which interacts with Annex 17, was included. For the sake of clarity and in consideration of reducing burden, the guidance also explicitly states that, for base prospectuses including indices as an underlying, supplements can be used to introduce disclosure about proprietary indices, and this should not be treated as a new type of underlying. This acknowledges the practical concern of frontloading base prospectuses with such disclosure, noting that an issuer may not ultimately issue such linked instruments. Guideline 2 Guideline 2: In relation to Annex 14 – Securities note for non-equity securities – and Annex 17 – Securities giving rise to payment or delivery obligations linked to an underlying asset – the assessment should be refined based on the type of underlying as per Item 3.1.7 (a) 22 of Annex 14 and Item 2.2.2 of Annex 17. This means that a supplement may include disclosure about the following types of underlying if the same type of underlying was included in the base prospectus:
Guideline 3
Guideline 3: In relation to Annex 19 – Asset-backed securities – the assessment should be refined based on whether a supplement involves Items 2.2.11 (a), 2.2.16 or 3.6 that were not previously included in the base prospectus. This means that a supplement should not be used to introduce disclosure in relation to a new obligor or entity guaranteeing the obligations as referred to in item 2.2.11 (a), new equity disclosure as referred to in item 2.2.16, or new disclosure for the reference asset or underlying as required by items 3.6 (a) or (c). Refined assessment for ESG-securities
54. The question of whether ESG-securities should be treated as a new "type" relative to nonESG counterparts was an important aspect of the CP. ESG-securities range from "plain
vanilla" types to highly structured ones, carrying degrees of inherent risks and investor expectations, which make it difficult to determine where to draw a line. The question is compounded by the upcoming Annex 23, which, following the general logic of the annexbased approach, suggests that ESG-securities could be treated as a new type simply due to the inclusion of disclosure from Annex 23 in a base prospectus for the first time. ESMA, however, recognises this might not always be proportionate.
55. Accordingly, considering the various factors and arguments for and against treating ESGsecurities as a new type, the final Guidelines limit the assessment to Sustainability-linked
non-equity securities 23
. Therefore, a supplement should not be used to add disclosure about Sustainability-linked non-equity securities 24 if they were not mentioned in the base prospectus. In contrast, disclosure related to use of proceeds bonds or European Green Bonds 25 may be added to a base prospectus providing for "regular" bonds. 23 The CDR on scrutiny and disclosure, as amended, refers to "sustainability-linked non-equity securities" in Annex 23, whereas the CP Annex (Clean) referred to "sustainability-linked bonds" in Annex 21. The latter is also the case in the Final Annex (Clean) as part of ESMA's technical advice. 24 Idem. 25 Section 5 referring to European Green Bonds in the CP Annex (Clean) and Final Annex (Clean) as part of ESMA's technical advice no longer features in Annex 23 of the CDR on scrutiny and disclosure, as amended. This reference reflects market feedback on the earlier version of Annex 21.
Guideline 4
Guideline 4: In relation to Annex 23 – Non-equity securities advertised as taking into account ESG factors or pursuing ESG objectives – the assessment should focus on whether the security amounts to a Sustainability-linked non-equity security as per Section 3 of that Annex. This means that a supplement should not be used to add disclosure in relation to Sustainability-linked non-equity securities if they were not previously included in the base prospectus.
56. The decision to limit the assessment to Sustainability-linked non-equity securities is based
on technical considerations. Unlike use-of-proceeds bonds and European Green Bonds, whose underlying mechanics are generally similar to "plain vanilla" bonds, Sustainabilitylinked non-equity securities are considered to possess features which distinguish them more significantly. For instance, they are typically tied to specific targets inherent to this type of instrument, which also make them quite different in appearance to "regular" nonESG structured products. In this case, ESMA's choice considers significant points in the feedback about investor protection, burden reduction, and broader ESG-related goals. It seeks to strike a balance based on all arguments presented and to generally align with the logic underpinning the Annex-based approach. Other points in the feedback
57. As outlined at the beginning of section 3.2, ESMA's response and rationale for the final
Guidelines addresses the main concerns raised in response to questions 1 to 6. They were largely centred around issues of clarity, practicality, and the need for greater certainty, all of which the annex-based approach should resolve. However, ESMA recognises that there are other specific matters warranting direct commentary, which are discussed in the following paragraphs.
58. Length of prospectuses: Question 3 in the CP specifically asked whether the proposed
approach in draft Guideline 2 would result in longer and more complex prospectuses. Responses were divided, but overall length appeared less an issue than the impractical cumulative effect of draft Guidelines 1 and 2. While the Annex-based approach may not necessarily solve for length, it should allay concerns about the cumulative impact since the approach has changed.
59. General proposals and two-track supplements: In addition to the Annex-based
approach, various proposals were put forward to address product supplements in response to question 5. Some were general suggestions about how to identify and regulate product
supplements. However, their broad and principled nature would make them challenging to apply in contrast to the Annex-based approach which was adopted.
60. Concerning the suggested two-track approaches to supplements, it is challenging to
determine how they would address the definition of a new security to fulfil the mandate in
Article 23(8) PR. More importantly, Article 23 PR does not currently envisage a two-track
approach to supplements. Adopting such an approach would likely require an amendment to the PR.
61. Cost/benefits of these proposed Guidelines: In response to question 6, some
respondents indicated that the proposal in the CP would not significantly increase costs. They even suggested that it would enhance legal certainty, convergence, and investor protection. However, a considerable number of respondents expressed serious concerns, highlighting that producing a base prospectus is significantly more expensive and resourceintensive (up to ten times more) than producing a supplement. The level of concern about these costs appeared to vary depending on the Member State. Respondents from certain Member States viewed the proposals as less problematic compared to others.
62. ESMA's adoption of the annex-based approach should help address these concerns. This
approach aims to mitigate the claim, raised in the feedback, that a proliferation in base prospectuses relative to supplements will materialise, while also ensuring better legal certainty, convergence, and investor protection. While it is acknowledged that the guidance introduces more regulation in this area, it is sufficiently high-level to facilitate burden reduction. In particular, it carries forward the principle in the CP that a supplement can be used when a base prospectus generally provides for a certain type of product. The measure of "generally provided for" is set at the level of a class of product and not granular features. For example, what is relevant is whether commodity-linked securities are generally provided for in the base prospectus as a class, and not whether the base prospectuses omit or includes references to oil, gas or gold. Similarly, if currency-linked securities are generally provided for in the base prospectus, the addition of previously omitted currencies such as the dollar or yen should not present an issue. Setting the threshold of "generally provided for" at the level of product class should help reduce burden and prevent difficult discussions about granular features.
63. Benchmarks: The concerns about front-loading base prospectuses for proprietary indices
should now be addressed, as the Guidelines explicitly state that a supplement can be used for index-linked securities if the base prospectus generally provides for that type of instrument. Beyond the subject of these Guidelines, ESMA acknowledges that the decision to limit the number of administrators in the benchmark register may impact disclosure in relation to structured products, but there are no further comments on that in this Final Report.
4 Annexes
4.1 Annex I - Summary of consultation questions
Q1: Do you agree with draft Guideline 1 proposed by ESMA and ESMA’s reasoning? If not, please explain why. Q2: Do you agree with draft Guideline 2 proposed by ESMA and ESMA’s reasoning? If not, please explain why. Q3: Do you believe draft Guideline 2 will lead to longer and less comprehensible prospectuses? If yes, please explain why and describe how you would solve this issue. Q4: The explanatory text under draft Guideline 2 identifies ‘green bonds’ and ‘sustainability-linked notes’ as distinct securities for the purpose of these Guidelines. Do you agree with that, or do you think they are the same as ‘regular’ bonds or ‘regular’ structured products? To the extent you consider ‘green bonds’ and ‘sustainabilitylinked notes’ to be the same as ‘regular’ bonds or ‘regular’ structured products, please explain why. In particular, make clear why, for example, a currency-linked note, or indexlinked note, should be treated differently to a ‘sustainability-linked note’ for the purpose of these Guidelines. Please also consider factors such as the oncoming Annex [21] in your response 26 . Q5: Is there another way to approach the subject of these Guidelines in your opinion? If yes, please explain what it is and provide arguments to support your suggested approach. Please also provide examples to illustrate the issue(s) you are solving and how your proposed approach facilitates that end. Q6: Can you provide an estimation of the costs/benefits of these proposed Guidelines? 26 The reference to Annex [21] relates to the proposed annex in ESMA’s consultation paper on draft technical advice concerning the Prospectus Regulation and on updating the CDR on financial information, supplements, advertisements and metadata. Section 5 of the consultation paper discusses the proposed annex. Annex [21] is also in ESMA's final report with technical advice concerning the Prospectus Regulation and the RTS updating the CDR on financial information, supplements and metadata. The corresponding annex number in the CDR on scrutiny on disclosure, as amended, is Annex 23.
4.2 Annex II - Mandate
Article 23(8) of the Prospectus Regulation states ESMA shall by 5 June 2026 develop
guidelines to specify the circumstances in which a supplement is to be considered to introduce a new type of security that is not already described in a base prospectus. Moreover, ESMA may generally issue guidelines under Article 16 of the ESMA Regulation.
4.3 Annex III – Guidelines specifying the circumstances in which a
supplement is to be considered to introduce a new type of security that is not already described in a base prospectus 1 Scope Who?
2 Legislative references, abbreviations and definitions
2.1 Legislative references
CDR on financial information, supplements, advertisements, and metadata Commission Delegated Regulation 2019/979 of 14 March 2019 supplementing Regulation (EU) 2017/1129 of the European Parliament and of the Council with regard to regulatory technical standards on key financial information in the summary of a prospectus, the publication and classification of prospectuses, advertisements for securities, supplements to a prospectus, and the notification portal, and repealing Commission Delegated Regulation (EU) No 382/2014 and Commission Delegated Regulation (EU) 2016/301 27 CDR on scrutiny and disclosure Commission Delegated Regulation (EU) 2019/980 of 14 March 2019 supplementing Regulation (EU) 2017/1129 of the European Parliament and of the Council as regards the format, content, scrutiny and approval of the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Commission Regulation (EC) No 809/2004 28 ESMA Regulation Regulation (EU) No 1095/2010 of the European Parliament and of the Council of 24 November 2010 establishing a European Supervisory Authority (European Securities and Markets Authority), amending Decision No 716/2009/EC and repealing Commission Decision 2009/77/EC 29 Listing Act Regulation (EU) 2024/2809 of the European Parliament and of the Council of 23 October 2024 amending Regulations (EU) 2017/1129, (EU) No 596/2014 and (EU) No 600/2014 to make public capital markets in the Union more attractive for companies and to facilitate access to capital for small and medium-sized enterprises 30 Prospectus Regulation or PR Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC 31 27 OJ L 166 21.6.2019, p. 1. 28 OJ L 166 21.6.2019, p. 26. 29 OJ L 331, 15.12.2010, p. 84. 30 OJ L 2024/2809, 14.11.2024 31 OJ L 168, 30.6.2017, p. 12.
2.2 Acronyms and Abbreviations
CP Consultation Paper
EC European Commission
EEA
ESFS
European Economic Area
European System of Financial Supervision
ESMA European Securities and Markets Authority EU European Union
2.3 Definitions
Competent authority an authority designated under Article 31 of the Prospectus Regulation Product supplement an abridged term to refer to a “supplement that is to be considered to introduce a new type of security that is not already described in a base prospectus.”
3 Purpose
4. These Guidelines are based on Article 23(8) of the Prospectus Regulation and Article
16(1) of the ESMA Regulation. The objective of these Guidelines is to clarify when a supplement is to be considered to introduce a new type of security that is not already described in a base prospectus drafted pursuant to Article 8 of the Prospectus Regulation and to establish consistent, efficient and effective supervisory practices within the ESFS and to ensure the common, uniform and consistent application of the provisions in Article 23(8) of the Prospectus Regulation. 4 Compliance and reporting obligations
4.1 Status of the guidelines
5. This document contains guidelines issued under Article 16 of the ESMA Regulation. In
accordance with Article 16(3) of the ESMA Regulation, competent authorities and financial market participants must make every effort to comply with guidelines and recommendations.
6. Competent authorities to whom the guidelines apply should comply by incorporating
them into their supervisory practice, including where particular guidelines within the document are directed primarily at financial market participants.
4.2 Reporting requirements
7. Competent authorities to which these guidelines apply must notify ESMA whether they
comply or intend to comply with the guidelines, with reasons for non-compliance, within two months of the date of publication by ESMA to cfr@esma.europa.eu. In the absence of a response by this deadline, competent authorities will be considered as noncompliant. A template for notifications is available from the ESMA website.
8. Financial market participants are not required to report whether they comply with these
guidelines.
5 Guidelines specifying the circumstances in which a supplement is to be considered to introduce a new type of security that is not already described in a base prospectus
5.1 Overview
9. Considering Articles 23(4a) and 23(8) of the Prospectus Regulation, these Guidelines
aim to clarify when a supplement is to be considered to introduce a new type of security that is not already described in a base prospectus drafted pursuant to Article 8 of the Prospectus Regulation.
5.2 The Guidelines
10. To ensure investor protection and foster regulatory convergence across the EU,
guidance is necessary to clarify the circumstances in which an assessment as to whether a supplement is to be considered to introduce a new type of security that is not already described in a base prospectus because a supplement should not add information about new types of securities into a base prospectus. These Guidelines clarify those circumstances and are designed to help financial market participants and national competent authorities make such assessment.
11. Guideline 1: If a supplement involves disclosure from the following securities
note annexes or building blocks that did not apply to the securities included in the base prospectus, the supplement should be treated as introducing a new “type” of security, and a new base prospectus should be required:
registration document via the supplement.
14. Guideline 2: In relation to Annex 14 – Securities note for non-equity securities –
and Annex 17 – Securities giving rise to payment or delivery obligations linked to an underlying asset – the assessment should be refined based on the type of underlying as per Item 3.1.7 (a) 32 of Annex 14 and Item 2.2.2 of Annex 17. This means that a supplement may include disclosure about the following types of underlying if the same type of underlying was included in the base prospectus:
For instance, if a base prospectus includes “index” as a possible type of underlying,
disclosure on new proprietary indices may be added via a supplement as this is not a new type of underlying based on this approach. However, a supplement should not include a commodity if the base prospectus does not include commodities as a type of underlying.
Additionally, in line with paragraph 13 of these Guidelines (with reference to Annex
21 – Guarantees), a supplement should not be used to introduce disclosure in relation to a new entity or issuer as referred to in Item 2.2.2 (a)(i) of Annex 17, unless the relevant disclosure is incorporated by reference using an approved and valid registration document.
Guideline 3: In relation to Annex 19 – Asset-backed securities – the assessment
should be refined based on whether a supplement involves Items 2.2.11 (a),
2.2.16 or 3.6 that were not previously included in the base prospectus. This
means that a supplement should not be used to introduce disclosure in relation to a new obligor or entity guaranteeing the obligations as referred to in item
2.2.11 (a), new equity disclosure as referred to in item 2.2.16, or new disclosure
for the reference asset or underlying as required by items 3.6 (a) or (c). 32 "Where the rate is not fixed:"
Additionally, in line with paragraph 13 of these Guidelines (with reference to Annex
21 – Guarantees), if such information is contained in a previously approved registration document or securities note then it could be included using a supplement. Otherwise, it should not.
Guideline 4: In relation to Annex 23 – Non-equity securities advertised as taking
into account ESG factors or pursuing ESG objectives – the assessment should focus on whether the security amounts to a Sustainability-linked non-equity security as per Section 3 of that Annex. This means that a supplement should not be used to add disclosure in relation to Sustainability-linked non-equity securities if they were not previously included in the base prospectus.
However, in the context of Annex 23, disclosure in relation to (i) non-equity securities
with ESG-related use of proceeds or (ii) structured non-equity securities advertised as having an ESG component or pursuing an ESG objective, may be added to the base prospectus using a supplement.
For the avoidance of doubt, the approaches laid down in preceding paragraphs also
apply to EU-Follow on and EU Growth issuances base prospectuses.
Note from RegAlert. AI assistants can read this document in full, and search 70,000+ more, through the RegAlert MCP connector (https://mcp.regalert.today/mcp). Free with an account. How to connect ChatGPT, Claude or Cursor.
RegAlert holds no document that amends or replaces this one. This is not a check that it is in force: confirm with the regulator.
“These Guidelines have been drafted pursuant to Article 23(8) of the Prospectus Regulation and Article 16(1) of the ESMA Regulation.”
“Article 23(8) of the Prospectus Regulation (PR) requires ESMA to “develop Guidelines to specify the circumstances in which a supplement is to be considered to introduce a new type of security that is not already described in a base prospec…”
More like this from ESMA
ESMA published 2 documents in the last 30 days. We email you each new one the day it's published.
Source: European Securities and Markets Authority — original document · Summary generated with machine assistance and checked by an AI reviewer before publication; the authoritative text is the regulator's original document. How RegAlert works
In RegAlert: added · updated